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suppressor gene, cytoglobin) are upregulated in lung cancer and strongly associated with 
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expression of hypoxia markers. These findings indicate their potential implications in the 
molecular pathogenesis and clinical outcome of non-small cell lung carcinomas. 
Abstract 
Collagen 1A1 (COL1A1), RNA–binding and pre-mRNA Processing Factor (PRPF40A) 
and Uncoupling Protein 2 (UCP2) were recently identified as downstream effector genes of 
cytoglobin (CYGB), which has been shown to be implicated in tumour biology. Although 
these three genes have been previously associated with cancer, little is known about their 
status in lung malignancies. In the present study, we investigated the expression and 
promoter methylation of COL1A1, PRPF40A and UCP2 in 211 non-small cell lung cancer 
(NSCLC) and adjacent normal tissue samples. We demonstrate that COL1A1 and PRPF40A 
mRNAs are significantly overexpressed in NSCLC (p<1x10-4), while UCP2 exhibits a trend of 
upregulation (p=0.066). Only COL1A1 promoter revealed hypermethylation in NSCLCs (36%), 
which was particularly evident in squamous cell carcinomas (p=0.024) and in the tumours 
with moderate to good differentiation (p=0.01). We did not observe correlation between 
DNA methylation and expression of COL1A1. However, mRNA level of COL1A1, as well as 
PRPF40A and UCP2 exhibited striking association with the expression of hypoxia markers: 
HIF1α and VEGFa (p≤0.001). In addition, we demonstrate in lung cancer cell lines exposed to 
hypoxia or oxidative stress that COL1A1 transcription significantly responds to oxygen 
depletion, while other genes showed modest upregulation in stress conditions. In 
conclusion, our data revealed that COL1A1, UCP2 and PRPF40A are novel players implicated 
in the complex network of hypoxia response in the NSCLC.  
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Introduction 
Lung cancer is among the most prevalent neoplastic diseases accounting for the 
highest mortality in both genders worldwide 1. Due to typically asymptomatic early stage 
and late diagnosis, lung tumours are difficult to treat as the therapeutic options become 
limited. The reduction of lung cancer mortality has been set as a major priority in the UK 
through the development of more efficient early diagnosis and intervention tools, both of 
which require better understanding of the molecular biology of the disease2. 
Our previous studies suggested cytoglobin (CYGB) as a putative tumour suppressor 
gene in lung 3 and oesophageal 4 tumours and successive in vitro and in vivo studies provided 
further evidence in support of this hypothesis 5-7. Nevertheless, CYGB was also associated 
with hypoxia and cancer aggressiveness 5, 8. Shivapurkar and co-workers identified three 
downstream effector genes of CYGB, which were downregulated in CYGB-overexpressing 
lung and breast cancer cell lines 6. These genes were: collagen 1A1 (COL1A1), RNA–binding 
and pre-mRNA Processing Factor (PRPF40A) and Uncoupling Protein 2 (UCP2). Interestingly, 
COL1A1, PRPF40A and UCP2 expression was linked to the metabolic pathways implicated in 
hypoxia and oxidative stress 9-12, events associated with more aggressive and therapy-
resistant tumours 13, 14. 
COL1A1 is an extracellular matrix protein, whose overexpression was linked to breast 
15, gastric 16 and colorectal tumours 17. UCP2 is a mitochondrial membrane protein 
transporting protons from the intermembrane space to mitochondrial matrix (i.e. 
uncoupling). Upregulation of UCP2 was reported in colon cancer 18, hepatocellular cancer, 
and cholangiocarcinoma 9. Finally, PRPF40A participates in assembly of splicing machinery 
onto the pre-mRNAs 19. Little is known about the involvement of PRPF40A in cancer. 
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However, its upregulation was reported in pancreatic cancer 20 and in the cells harbouring 
various p53 cancer-related mutations 21. 
In previous microarray analyses, COL1A1 22 and UCP2 23 were found upregulated in 
various malignant tissues, including lung cancer. However, no single-gene validation of these 
results in lung cancer has been presented so far. Thus, we aimed to explore UCP2, PRPF40A 
and COL1A1 mRNA expression and promoter methylation in order to determine their 
molecular profile in NSCLC and  their association to clinicopathological parameters and 
hypoxia markers.  
Material and methods 
Tissue collection  
NSCLC and adjacent normal tissues were collected from 156 patients operated 
between 1995 and 2005 at the Liverpool Heart and Chest Hospital, UK. All patients 
submitted informed consent and the study was approved by the local ethics committee. The 
patient group [described in 24] represents typical cohort with resectable lung tumour as 
decided following standard treatment procedures. It consisted of 99 males and 57 females, 
with the mean age 65.7 (range: 40 - 87). This set contained two most frequent histological 
subtypes: squamous cell lung cancer (SqCLC) (N=86) and adenocarcinoma (N=70). With 
regard to the pathological stage, tumours were split in the following groups:  T1 (N=11), T2 
(N=125), T3 (N=15) and T4 (N=5), while according to differentiation status the group 
breakdown was: poor (N=48) and moderate/good (N=107). Nodal metastasis occurred in 75 
cases, while 80 patients had metastasis-free nodes. The follow-up data included 12 alive and 
57 dead patients. The samples were snap frozen and grossly micro-dissected to ascertain 
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more than 80% tumour tissue. All the methylation and expression values were included in 
the analysis, even in the absence of normal, methylation or expression counterpart data for 
the given patient. Overall, we utilised RNA from 128 normal and 146 NSCLC tissues and DNA 
from 26 normal and 91 NSCLC tissues.  
 
Cell lines 
Adenocarcinoma (H358) and SqCLC (CALU1) lung cancer cell lines (ATCC) were 
maintained at 37°C/5% CO2 in DMEM/F-12/Glutamax™-I (Invitrogen) with 10% FBS. For 
hypoxic studies the cells were cultured at 1% O2 for 48h, while oxidative stress was achieved 
with 300µM H2O2 treatment for 24h. H2O2 concentration was chosen as an IC50 of CALU1 
according to our survival curve. 
 
Promoter methylation  
 DNA extraction, bisulfite conversion and pyrosequencing analyses were performed as 
described 24. PCR reactions were performed with HotStarTaq®Plus Mastermix (Qiagen) 
according to manufacturer’s protocol with 85ng bisulfite-converted DNA and 0.16µM 
primers. The following PCR primers (MWG Operon) were used: COL1A1_F 
GGAGAGAAGGTAAATGGAAG, COL1A1_R-biotinylated AACCTAACCCCAACCCTA, PRPF40A_F 
GAGTAGAGAATAGAGAGGATTTG, PRPF40A_R-biotinylated TAATCAAAACCCAAAAAAC, 
UCP2_F-biotinylated GTTTTGGGATTGATTGTT and UCP2_R CAAAACTAAAACCAAACTCAC. For 
pyrosequencing reaction 0.33µM sequencing primer was used: COL1A1_S 
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(GAGAAGGTAAATGGAAGA), PRPF40A_S (ATAGAGAGGATTTGGA) and UCP2_S 
(AAACTAAAACCAAACTC).  
 
Gene expression 
 RNA isolation, reverse transcription, qPCR and data analysis were previously 
described 24. The following primer/probe mixes were used in the qPCRs: COL1A1 
(Hs01076780_g1), PRPF40A (Hs00215465_m1) and UCP2 (Hs01075225_m1) (Life 
Technologies). 
 
GSH-Glow™ Glutathione Assay 
Cellular level of glutathione was measured with the GSH-Glow™ Glutathione Assay 
(Promega) on Genios plate reader (Tecan) according to manufacturer’s instructions. The 
luminescence values were normalised to  the total protein level as assessed with the DC 
Biorad Assay (Biorad).  
 
Statistical analysis 
 Non-parametric tests were used for statistical analyses (PASW Statistics 18.0, SPSS) as 
1-sample Kolmogorov-Smirnov test showed skewed distribution of continuous variables. 
Pairwise comparisons between normal and NSCLC samples were performed with Wilcoxon 
test. The differences for continuous variables among independent cohorts within clinical 
parameters were determined with the Kruskal-Wallis and Mann-Whitney tests. Bivariate 
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correlation was probed with Spearman’s test and Bonferroni correction was applied to 
adjust for multiple comparisons. Patients’ survival was calculated with the log rank test. 
Results 
Gene expression analysis of COL1A1, PRPF40A and UCP2 in NSCLC 
Our comparative qPCR analysis showed abundant COL1A1 overexpression in tumours 
(median RQ=975.4, IQR: 389.9-3172.7, N=132) when compared to adjacent normal tissues 
(69.4, 29.8-235.6, N=119, Mann-Whitney test, p<1x10-4) (Fig.1A). Similarly, PRPF40A was 
overexpressed in NSCLC samples (RQ=3.49, 1.13-11.84, N=135 vs 1.53, 0.98-3.16, N=119, 
Mann-Whitney test, p<1x10-4) (Fig.1B). In the case of UCP2, there was only a trend of higher 
expression observed in lung tumours (RQ=0.043, 0.025-0.08, N=136 vs 0.034, 0.026-0.055, 
N=122, Mann-Whitney test, p=0.066) (Fig.1C). UCP2 mRNA expression was higher in lung 
adenocarcinomas (RQ=0.053, 0.03-0.087, N=61) than in SqCLCs (RQ=0.035, 0.019-0.072, 
N=75, Mann-Whitney test, p=0.015). Apart from that no other associations were observed 
between COL1A1, PRPF40A or UCP2 mRNA expression and patients’ gender, age, survival, 
smoking history, TNM classification, tumour histology and differentiation. 
 
Promoter methylation analysis of COL1A1, PRPF40A and UCP2 in NSCLC 
 DNA for promoter methylation analysis was available for 91 of the NSCLC patients. 
We set the hypermethylation threshold according to a previously described method (Normal 
reference range = mean MtI + 2 x standard deviation of the normal samples) 24 at MtI=19.9% 
for UCP2 and MtI=13.0% for COL1A1. PRPF40A promoter was unmethylated in all samples 
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tested.  UCP2 promoter hypermethylation was observed only in 5/91 NSCLC samples and 
none (0/26) of the normal tissues analysed. We noted elevated COL1A1 promoter 
methylation in 33/91 NSCLCs (Fig.1D) and in 2/26 normal samples. Although the difference 
in methylation between grouped normal and tumour samples was insignificant, pairwise 
comparison showed significant hypermethylation of COL1A1 promoter in NSCLC (p=0.035, 
Wilcoxon test). Higher methylation was observed in SqCLCs (median MtI=8.72%, IQR: 1.95-
26.18, N=56) than in adenocarcinomas (2.28, 1.36-5.5, N=35, Mann-Whitney test, p=0.024, 
Fig.1E), as well as in the moderately and well differentiated tumours (MtI=5.19%, IQR: 1.99-
28.21, N=65) in comparison to poorly differentiated NSCLCs (2.18, 1.39-5.45, N=26, Mann-
Whitney test, p=0.01, Fig.1F). Apart from that observation COL1A1 methylation did not 
correlate with patients’ gender, age, survival, smoking history and TNM classification. 
Moreover, methylation was not associated with the mRNA expression values, even when 
potentially confounding factors (histology, differentiation) were taken into account. 
 
COL1A1, PRPF40A and UCP2 expression correlates with hypoxia markers 
Next, we evaluated interrelationships between COL1A1, PRPF40A, UCP2 and hypoxia 
markers (CYGB, Hypoxia-Inducible Factor 1α - HIF1α and Vascular Endothelial Growth Factor 
- VEGFa), whose expression profiles were previously reported 24. PRPF40A exhibited the 
strongest hypoxia association pattern among all genes under investigation (Table 1). Its 
mRNA expression level correlated with CYGB (ρ=0.7, p<1×10-4, N=128), HIF1α (ρ=0.841, 
p<1×10-4, N=129) and VEGFa (ρ=0.677, p<1×10-4, N=95). The hypoxia dependence was 
observed as well in the case of COL1A1, whose expression was associated with CYGB 
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(ρ=0.677, p<1x10-4, N=128), HIF1α (ρ=0.646, p<1x10-4, N=127) and, to a lesser extent, with 
VEGFa (ρ=0.356, p=5.8x10-4, N=90). Similar relationships were seen in the case of UCP2 
(UCP2 vs CYGB: ρ=0.38, p<1x10-4, N=129, UCP2 vs HIF1α: ρ=0.596, p<1x10-4, N=130 and vs 
VEGFa: ρ=0.343, p=7.1x10-4, N=94). The expression profiles of COL1A1, PROPF40A and UCP2 
genes correlated with each other. The strongest positive association was observed between 
PRPF40A and COL1A1 (ρ=0.612, p<1x10-4, N=129), PRPF40A and UCP2 (ρ=0.596, p<1x10-4, 
N=132), while the weakest – between COL1A1 and UCP2 (ρ=0.353, p<1x10-4, N=128).  
 
COL1A1, PRPF40A and UCP2 expression under stress conditions in vitro 
Hypoxia response is activated not only with oxygen depletion, but also with nutrient 
deficiency, oxidative stress and other signalling pathways. Therefore, we wanted to assess 
whether COL1A1, PRPF40A and UCP2 might be regulated by hypoxia and/or oxidative stress 
in vitro. Cellular response to oxidative and hypoxic stress was confirmed by testing 
glutathione content (Fig.2A) and the mRNA expression level of VEGFa (Fig.2B), respectively. 
COL1A1 became upregulated in hypoxic conditions in both cell lines, however this was 
significant only in CALU1 (RQ=3.15±0.8 vs 1.0±0.07 in normoxic cells, p=0.02, Mann-
Whitney), but not in H358 (RQ=2.2±0.7 vs 1.1±0.06, p=0.074). PRPF40A and UCP2 expression 
little changed at 1% O2, as only CALU1 cell line exhibited modest upregulation of UCP2 
(RQ=1.5±0,24 vs 0.9±0.15, p=0.04, Mann-Whitney). Similarly, oxidative stress did not evoke 
significant changes in the expression of COL1A1, UCP2 and PRPF40A genes.  
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Discussion 
Although UCP2, PRPF40A and COL1A1 upregulation has been previously observed in 
malignant tissues 20, 22, 23 and associated to response to hypoxia and oxidative stress 9-12, little 
is known about their status in lung cancer. The data presented hereby demonstrate a trend 
of overexpression of UCP2 and significant overexpression of COL1A1 and PRPF40A in NSCLCs 
compared to adjacent normal tissues. Moreover, expression of all three genes correlated 
with that of hypoxia markers: CYGB, HIF1α and VEGFa. We also observed that PRPF40A 
promoter remained unmethylated, while UCP2 promoter was sporadically methylated in few 
cancer samples. Interestingly, we demonstrated a trend of increased methylation within 
COL1A1 promoter in a subset of NSCLCs, however, it did not associated with  COL1A1 
expression. This might be due to insufficient sample number taken into analysis, existence of 
another promoter controlling COL1A1 expression or presence of a potent factor that affects 
COL1A1 mRNA content more profoundly than DNA methylation, e.g. tumour hypoxia. 
Indeed, COL1A1 expression strongly correlates with hypoxia markers in tissues and becomes 
upregulated as well in low oxygen tension in our cell line model. Thus, the effect of hypoxia 
may be masking the methylation events observed in the subset of the NSCLC tissues. 
Surprisingly, our data indicate positive correlation of COL1A1, UCP2 and PRPF40A with CYGB 
expression, which has been previously shown to be inverse in in vitro experiments 6. In the 
data published by Shivapurkar et al, transient CYGB overexpression resulted in >2-fold 
downregulation of the three genes, however this effect was less pronounced and 
reproducible in the cells with stable CYGB overexpression. While in vivo data not always 
recapitulate in vitro observations, prolonged tumour hypoxia identified in our tissue set may 
additionally modify the interdependence of CYGB and its proposed downstream effectors. 
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Despite the clustering of the three genes with hypoxia markers in tissues, in vitro 
hypoxia had differential effect on their expression. The statistical correlation between 
various genes might reflect similar, but unrelated expression patterns. These patterns could 
manifest the specificity of pathologic transcriptome rather than the activation of a particular 
signalling pathway. From this point of view, lack of responsiveness in the cells incubated at 
low O2 level may indicate independence of PRPF40A and UCP2 from hypoxia in NSCLCs. 
Alternatively, the expression of PRPF40A and UCP2 may require additional stimulators, 
which are present in tumour microenvironment in vivo, but absent in vitro (e.g. more acute 
O2 deficit, cytokine release, interactions with extracellular stroma) 
25. It is possible as well 
that in the lung cancer setting, UCP2 and PRPF40A act upstream of hypoxia pathways, thus 
inducing expression of HIF1α independently of the O2 tension. 
Whilst UCP2 overexpression might contribute to Warburg effect and promote 
tumourigenic phenotype 23, the implications of deregulated expression patterns of PRPF40A 
and COL1A1 remain to be elucidated.  It is likely, however, that these genes may assist in the 
adaptive responses to oxidative stress and hypoxia / reoxygenation events, thus promoting 
tumour aggressiveness, metastasis and treatment resistance. As the three latter issues are 
pertinent to cancer patient management, it would of interest to investigate this hypothesis 
in the future.  
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Table 
Table 1. Association between mRNA expression levels of COL1A1, PRPF40A, UCP2, CYGB, 
HIF1α and VEGFa assessed with Spearman’s correlation test. Rho-values (correlation 
coefficient), p-values and the number of samples for each analysis are provided. Each 
correlation appear significant after Bonferroni correction. 
Table 1.  
 
PRPF40A  UCP2  CYGB HIF1α  VEGFa  
COL1A1  
Rho=0.612, 
p<1x10-4,  
N=129  
Rho=0.353,  
p<1x10-4,  
N=128  
Rho=0.677, 
p<1x10-4, 
N=128 
Rho=0.646,  
p<1x10-4,  
N=127  
Rho=0.356, p=5.8x10-4, 
N=90 
PRPF40A  
 
Rho=0.596,  
p<1x10-4,  
N=132  
Rho=0.7, 
p<1x10-4, 
N=128 
Rho=0.841, 
 p<1x10-4,  
N=129  
Rho=0.677,  
p<1x10-4,  
N=95  
UCP2  
  
Rho=0.38, 
p<1x10-4, 
N=129 
Rho=0.596,  
p<1x10-4,  
N=130  
Rho=0.343, p=7.1x10-4,  
N=94  
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Figure legend 
Figure 1. Boxplot representation of (A) COL1A1, (B) PRPF40A and (C) UCP2 mRNA levels in 
NSCLC and adjacent normal tissues. (D) COL1A1 promoter methylation profile in NSCLC and 
normal samples, (E) in adenocarcinomas and SqCLCs, (F) and in the tumours with poor and 
moderate to good differentiation. Number of cases analysed with the Mann-Whitney (A-C, E, 
F) or Wilcoxon (D) test  and corresponding p-values are provided. Representative pyrograms 
of COL1A1 promoter for normal (G) and NSCLC (H) samples analysed with pyrosequencing. 
X-axis indicates nucleotide dispensation order, while Y-axis luminescence intensity for each 
incorporated nucleotide. Boxes above the graphs show the percentage of methylated 
cytosines for each CpG site. 
Figure 2. Glutathione (GSH) level normalised to total protein content (A) CALU1 and H358 
cell lines after incubation with 300µM H2O2 (N=6). Relative mRNA expression of (B) VEGFa, 
(C) COL1A1, (D) PRPF40A and (E) UCP2 in CALU1 and H358 cell lines after incubation at 1% O2 
(H) or 300µM H2O2 (O). Columns represent mean (N=4) RQ values (±SEM) calibrated against 
untreated (N) control cells. * p<0.05 (Mann-Whitney test). 
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